ArticleScientific reports2026
Polyphenol-rich extra-virgin olive oil influences bioenergetics and may modulate NLRP3 inflammasome in PBMCs from children and adolescents with obesity.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Paediatric obesity is characterized by chronic inflammation and immunometabolic dysregulation. Extra-virgin olive oil (EVOO) polyphenols exert antioxidant and immunomodulatory effects that may counteract obesity-related alterations. A 12-week controlled nutritional intervention was conducted in 84 children and adolescents with obesity (BMI > 95th percentile), comparing a Mediterranean diet supplemented with either high-polyphenol EVOO (P-EVOO) or refined olive oil (R-OO). Anthropometric and biochemical parameters were evaluated at baseline and study completion. In peripheral blood mononuclear cell (PBMC) of a sub-cohort, bioenergetic analyses, gene expression related to mitochondrial biogenesis, antioxidant defence, and NLRP3 gene expression were assessed. Both groups exhibited significant reductions in BMI, waist circumference, LDL cholesterol, triglycerides and uric acid. A significant reduction in insulin resistance was observed exclusively in the P-EVOO group. In PBMCs, P-EVOO enhanced mitochondrial respiration and ATP production, associated with a metabolic shift toward oxidative phosphorylation. This was accompanied by increased mitochondrial biogenesis and activation of the Nrf2-SOD2 antioxidant axis. P-EVOO upregulated NLRP3, IL-1β, CASP8 and CASP1 gene expression, without IL-18 or GSDMD increase, suggesting a distinct expression pattern of alternative NLRP3 inflammasome-associated markers. These findings indicate that P-EVOO could ameliorate metabolic health and mitochondrial bioenergetics in paediatric obesity, promoting an oxidative immunometabolic phenotype potentially associated with controlled inflammasome transcriptional regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.